Kaplan-Meier survival analysis by baseline proliferative rate. Comparison of median overall survival for patients with multiple myeloma who achieved a PCLI response versus PCLI nonresponders who had (left) high baseline PCLI (≥ 3%), (middle) intermediate PCLI (> 1% but < 3%), and (right) low PCLI (< 1%).